A trial fibrillation (AF) is associated with high morbidity and mortality, with an increased risk of stroke and thromboembolism.
are limited data on the prognostic role of biomarkers in anticoagulated patients with AF in relation to adverse events (including thromboembolism), mortality, and major bleeding. However, recent studies of biomarkers in AF have shown that they could substantially improve risk stratification. 9 Indeed, it has been described in 2 large trials of patients with AF, which compared the efficacy and safety of new oral anticoagulants against warfarin, how several biomarkers (like troponins or N-terminal pro-B-type natriuretic peptide [NT-proBNP] ) are predictive for adverse events. 10, 11 We recently reported in a large real-world cohort of anticoagulated patients with AF that von Willebrand factor levels (an established biomarker of endothelial damage/dysfunction) were independent predictors for thrombotic, bleeding events and death during a 2-year follow-up period. 12 Indeed, biomarkers may potentially be used to refine stroke and bleeding risk stratification in AF.
Elevated levels of NT-proBNP are important markers of increased mortality and morbidity in congestive heart failure and ischemic heart disease, 13 and are even predictive for AF. 14 The aim of our study was to assess prognostic value to NT-proBNP levels in an unselected real-world cohort of anticoagulated patients with AF seen in everyday clinical practice.
Methods Patients
We recruited consecutive patients with permanent or paroxysmal AF who were taking OAC from our outpatient anticoagulation clinic. To homogenize the study sample, all patients had good anticoagulation control with stable international normalized ratio (INR) values for ≥6 months (INRs, 2.0-3.0, time in therapeutic range >70%), and were anticoagulated with acenocoumarol. Patients with prosthetic heart valves, acute coronary syndrome, stroke (ischemic or embolic), valvular AF, potentially unstable chest pain, or any hemodynamic instability as well as patients who had hospital admission or surgical intervention in the preceding 6 months were excluded from the study. Patients with previous stroke occurring >6 months from the inclusion date were eligible. At study entry, a complete medical history was recorded.
The CHA 2 DS 2 -VASc stroke risk score was recorded as baseline measures of stroke risk. 4, 6 CHADS 2 is based on a point system in which 2 points are assigned for a history of stroke or transient ischemic accident, and 1 point is assigned for age ≥75 years, hypertension, diabetes mellitus, or congestive cardiac failure. The CHA 2 DS 2 -VASc risk score assigns 1 point to congestive heart failure, hypertension, diabetes mellitus, vascular disease, age 65 to 74 years, and sex category (female) and 2 points to age ≥75 years and stroke. The 1 point to hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly (≥65 years of age), and concomitant drug/alcohol use (1 point each; HAS-BLED) risk score was calculated as a measure of baseline bleeding risk as a result of adding 1 point to hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile INR, elderly (age ≥65 years), and concomitant drug/alcohol use in excess (1 point for each). 15 Based on our inclusion criteria at study entry, labile INR was scored as 0 in every patient (ie, all patients had good INR control), and renal impairment was recorded from medical history of the patients.
Follow-up information was obtained from visits through the anticoagulation clinic, the hospital electronic medical records system or, when unavailable, by telephone interview. The primary end point was stroke/transient ischemic accident, which included both cardioembolic and atherothrombotic strokes, as well as systemic embolism. The secondary end point was the composite of cardiovascular events defined as stroke/transient ischemic accident, including both cardioembolic and atherothrombotic strokes, as well as systemic embolism, acute coronary syndrome, acute heart failure and cardiac death.
We also recorded as secondary end points the occurrence of major bleeding (defined by the International Society of Thrombosis and Haemostasis criteria) 16 and all-cause deaths.
Blood Samples and Laboratory Analysis
Blood samples were drawn atraumatically and without stasis into syringes preloaded with trisodium citrate (0.011 mol/L). Platelet-poor plasma fractions were obtained by centrifugation at 4°C for 20 minutes at 2200 g. Aliquots were stored at −80°C to allow batch analysis. NT-proBNP levels were assessed by electrochemiluminescence in an automated analyser (Cobas e 601; Roche Diagnostica; Mannheim, Germany). The intra-assay variation coefficient was 5.6%. The intra-assay coefficient of variation for NT-proBNP was 1.8% for 221 pg/mL and 3.1% for 4250 pg/mL.
Statistical Analysis
Continuous variables were tested for normal distribution by Kolmogorov-Smirnov test. Continuous variables are presented as a mean±SD or median (interquartile range), as appropriate, and categorical variables as a percentage. We explored the best cutoff points for NT-proBNP in our study population, and receiver-operating characteristic curves analyses were generated to test the predictive discrimination cutoff to identify association with adverse events during follow-up. The cut point with the best sensitivity and specificity was chosen. The independent effect of NT-proBNP on prognosis was assessed using a Cox proportional hazards regression model, incorporating the CHA 2 DS 2 -VASc score into the multivariate model for the primary end point, as well as the composite of cardiovascular events and death; and for major bleeding events, adjustment was by HAS-BLED score. The impact of adding renal dysfunction was also explored in a secondary multivariate analysis. Model performance was evaluated by calculating C-statistics, and the improvement in predictive accuracy was evaluated by calculating the net reclassification improvement (NRI) and integrated discrimination improvement (IDI), as described by Pencina et al, 17 in which the categories of probability for events are defined based on prognostication scheme of the CHADS2 or CHA2DS2-VASc. A P value <0.05 was accepted as statistically significant. Statistical analysis was performed using SPSS 15.0 for Windows (SPSS, Inc; Chicago, IL).
Results
We studied 1172 patients (49% male; median age 76 years) whose clinical characteristics are shown in Table 1 . The median CHA 2 DS 2 -VASc score was 4 (3-5), and 94% had a CHA 2 DS 2 -VASc score ≥2. Median follow-up was 1007 (806-1279) days and, during this period, 51 patients presented with the primary end point stroke (1.6% per year), whereas 143 patients (4.51% per year) died, and 128 patients had an adverse cardiovascular event (4.04% per year).
Median levels (interquartile range) of NT-proBNP were 610 (318-1037) pg/mL. For each end point, we constructed receiver-operating characteristic curves that gave a cutoff point of 822 pg/mL for the primary end point of stroke/embolism (area under the curve, 0.63; 95% confidence interval, 0.60-0.66; sensitivity, 61%; specificity, 66%; positive predictive value, 8%; and negative predictive value, 97%). Second, we identified a cutoff point of 519 pg/mL for mortality (area under the curve, 0.59; 95% confidence interval, 0.56-0.62; sensitivity, 70%; specificity, 45%; positive predictive value, 15%; and negative predictive value, 92%). Third, we identified a cutoff point of 304 pg/mL for adverse cardiovascular events (area under the curve, 0.57; 95% confidence interval, 0.54-0.59; sensitivity, 87%; specificity, 25%; positive predictive value, 12%; and negative predictive value, 94%). For
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bleeding events, we were not able to find a potential cutoff point (area under the curve, 0.525). Univariate predictors of stroke/embolism, adverse cardiovascular events, major bleeds, and mortality are shown in Table 2 .
On multivariate analysis, high NT-proBNP levels remained significantly associated with prognosis even after adjusting for CHA 2 DS 2 -VASc score. The CHA 2 DS 2 -VASc score had a hazards ratio (HR) of 1.30 (1.09-1.55), P=0.004, and high NT-proBNP (≥822 pg/mL) had an HR of 2.71 (1.54-4.75), P=0.001, for stroke. The influence of CHA 2 DS 2 -VASc score for the composite of cardiovascular events was 1.35 (1.21-1.51; P<0.001), and for high NT-proBNP (≥304 pg/mL), 1.85 (1.12-3.04; P=0.016). For all-cause mortality, the CHA 2 DS 2 -VASc score had an HR of 1.39 (1.26-1.55; P<0.001), and high NT-proBNP (≥519 pg/mL) had an HR of 1.66 (1.16-2.37; P=0.006). Only the HAS-BLED score was predictive for bleeding.
When renal dysfunction was added into the multivariate analysis, the presence of renal impairment only had a significant impact on death (HR, 1.59; 95% confidence interval, 1.03-2.45) and not the primary end point (stroke) nor the composite of cardiovascular events. Of note, the CHA 2 DS 2 -VASc score and NT-proBNP remained significant predictors of stroke, the composite of cardiovascular events, and death (full data not shown).
The IDI analysis demonstrated NT-proBNP-improved CHA 2 DS 2 -VASc score for predicting embolic events (relative IDI, 2.8%; P=0.001) and all-cause death (relative IDI, 1.8%; P=0.001). Similarly, the NRI showed significantly improved reclassification when NT-proBNP was added to the CHA 2 DS 2 -VASc score for stroke (P=0.047), composite cardiovascular events (P<0.001), and death (P=0.006; Table 3 ).
Discussion
Our study shows how increased plasma NT-proBNP, an established cardiovascular morbid-mortality marker, is associated with adverse prognosis in patients with AF concerning cardiovascular events, stroke, and systemic embolism and mortality. ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; CHA 2 DS 2 -VASc, 1 point to congestive heart failure, hypertension, diabetes mellitus, vascular disease, age 65-74 years, and sex category (female) and 2 points to age ≥75 years and stroke; HAS-BLED, 1 point to hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history or predisposition, labile international normalized ratio, elderly (≥65), and drugs/alcohol concomitantly (1 point each); IQR, interquartile range; NT-proBNP, N-terminal pro-B-type natriuretic peptide; and TIA, transient ischemic accident. by guest on December 30, 2017 http://stroke.ahajournals.org/
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Importantly, the addition of NT-proBNP resulted in an improved prediction performance for end points, beyond the CHA 2 DS 2 -VASc risk stratification scores. Specifically, NT-proBNP improved the prediction of those patients who had the primary end point (stroke) by 17%, assessed by the NRI analysis.
B-type natriuretic peptide is a 32-amino acid polypeptide secreted by ventricular myocytes mainly in response to increased wall tension such as volume or pressure overload.
B-type natriuretic peptide is cleaved into the active hormone (B-type natriuretic peptide) and the inactive NT-proBNP. 14 Circulating levels of NT-proBNP have been reported as markers of increased mortality and morbidity in congestive heart failure, ischemic heart disease, and even in community-based healthy subjects. 18 B-type nautriuretic peptides have also been used to predict the risk of AF. In this setting, BNP was reported as an CHA 2 DS 2 -VASc indicates 1 point to congestive heart failure, hypertension, diabetes mellitus, vascular disease, age 65-74 years, and sex category (female) and 2 points to age ≥75 years and stroke; CI, confidence intervals; IDI, integrated discrimination improvement; NRI, net reclassification improvement, and NT-proBNP, N-terminal pro-B-type natriuretic peptide. NT-proBNP 1.00 (1.00-1.00)*; 0.421
The predictive value of high N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels was adjusted by CHA 2 DS 2 -VASc score for stroke and systemic embolism, composite of adverse cardiovascular events, mortality, and by HAS-BLED score for major bleeds. CHA 2 DS 2 -VASc indicates 1 point to congestive heart failure, hypertension, diabetes mellitus, vascular disease, age 65-74 years, and sex category (female) and 2 points to age ≥75 years and stroke; CI, confidence intervals; HAS-BLED, 1 point to hypertension, abnormal renal/liver function (1 point each), stroke, bleeding history, or predisposition, labile international normalized ratio, elderly (≥65 years of age) and drugs/ alcohol concomitantly (1 point each); and HR, hazards ratio.
*It denotes the complete absence of significance.
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independent predictor of new-onset AF in patients with ST elevation myocardial infarction, 19 and elevated NT-proBNP levels predict an increased risk of development of AF independent of other risk factors including echocardiographic parameters. 20 In addition, it has also been reported that B-type natriuretic peptides, in combination with other biomarkers, could better identify cardioembolic stroke, 21, 22 even detecting new AF onset in patients admitted with acute stroke. 23 However, the RE-LY study (Randomized Evaluation of Long-Term Anticoagulation Therapy) was the first, which draws on the use of NT-proBNP as event predictor in anticoagulated patients with AF for stroke and mortality. 10 These results were corroborated by the ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation), which also showed an improved risk stratification value with this biomarker.
11
Currently used clinical risk scores have shown limited capability in predicting thromboembolic events, with low values for area under the curve, and also modest discriminating value for C-statistics. 7 Hence, it seems the fact that different recent studies have highlighted the incorporation of biomarkers to improve the prediction power of these scores, enhancing the risk stratification. We showed how NT-proBNP significantly improves the prediction ability of the CHA 2 DS 2 -VASc score in terms of C-statistics, IDI, and NRI. It is valuable to state that in the context of clinical trials, patients are often carefully selected, whereas patients with AF in real-life clinical practice tend to be older, with associated comorbidities and polypharmacy, factors that may make accurate estimation of stroke and bleeding risk more difficult.
There is a close relationship between AF-stroke and NT-proBNP. It has been reported that the origin of BNP in AF comes from myocyte stress secondary to atrial dysfunction, 24, 25 which, in turn, could be a mechanism of atrial embolization. 26, 27 Much of the AF-associated morbidity and mortality is secondary to a 5-fold to 6-fold increased risk of stroke. 28 Although oral anticoagulation is highly effective in reducing the risk for stroke and thromboembolism, the incidence of stroke in patients with AF with adjusted oral anticoagulation ranged from 1.2% to 2.0% per year. 29 We recently demonstrated how CHA 2 DS 2 -VASc score predicted adverse cardiovascular events beyond thromboembolic risk in patients with AF taking OAC 8 ; NT-proBNP could better identify patients at risk of stroke and other cardiovascular events, leading to better oral anticoagulant management or use of the new oral anticoagulants.
Limitations
A selection bias could be evident because we only recruited patients on stable OAC. Therefore, those unstable patients who are more prone to have adverse events were excluded, and we could discharge that high NT-proBNP levels would be secondary to any hemodynamic instability. Also, we have only determined a unique value of NT-proBNP; changes in this biomarker may occur during follow-up; and these modifications could give additional information. Importantly, BNP levels not only increase during states of hemodynamic stress, but also with age or renal dysfunction. 30 Unfortunately, we did not have detailed echocardiographic assessments in this real-world study to be able to assess other parameters potentially influencing NT-proBNP, including left atrial volume, valvular heart disease, etc.
In conclusion, in a real-world large cohort of patients with AF, we corroborated the prognostic and independent value of NT-proBNP in predicting new stroke events as well as mortality despite use of oral anticoagulation. This biomarker also permits us to refine stroke risk assessment using the current stroke stratification schemes based on clinical criteria. 
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